Targeting signaling pathways in multiple myeloma: Pathogenesis and implication for treatments

Area of Science:

• Hematologic Malignancies
• Cancer Biology
• Molecular Oncology

Background:

• Multiple myeloma (MM) is a significant hematologic malignancy characterized by bone lesions, anemia, hypercalcemia, and renal failure.
• Despite therapeutic advances, most MM patients eventually relapse, highlighting the need for novel treatment strategies.
• Signaling pathways are implicated in MM cell proliferation, survival, migration, and drug resistance.

Purpose of the Study:

• To review major signaling pathways involved in multiple myeloma pathogenesis.
• To discuss therapeutic strategies targeting these key pathways in MM.

Main Methods:

• Literature review of signaling pathways in multiple myeloma.
• Analysis of the role of PI3K/Akt/mTOR, Ras/Raf/MEK/MAPK, JAK/STAT, NF-κB, Wnt/β-catenin, and RANK/RANKL/OPG pathways.
• Examination of therapeutic approaches targeting these pathways.

Main Results:

• Several signaling pathways, including PI3K/Akt/mTOR, Ras/Raf/MEK/MAPK, JAK/STAT, NF-κB, Wnt/β-catenin, and RANK/RANKL/OPG, are critical in MM.
• Dysregulation of these pathways contributes to MM development and progression.
• Targeting these pathways offers potential for novel MM therapies.

Conclusions:

• Understanding the role of specific signaling pathways is essential for advancing multiple myeloma treatment.
• Targeted therapies against these pathways hold promise for overcoming treatment resistance and improving patient outcomes.